JSPRW — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-14

• o Briquilimab demonstrated a rapid onset of clinical efficacy with clinical responses seen as early as 1 week post-dose and complete responses observed as early as week 2 post-dose.

• o Briquilimab drove deep and meaningful clinical responses with 100% complete responses through 8 weeks demonstrated at the 240mg dose level.

• o Briquilimab was well-tolerated and demonstrated a favorable safety profile:

• ● KIT-related adverse events (“AEs”) were generally transient, low-grade events;

• ● The majority of AEs observed were resolved while on study prior to subsequent doses; and

Text removed vs the prior filing · source: 10-Q · 2025-11-10

• ● our investigation into a drug product lot used in our Phase 1b/2a BEACON study in CSU and Phase 1b/2a ETESIAN study in asthma, and the results of such investigation;

• ● Briquilimab demonstrated a rapid onset of clinical efficacy:

• o Clinical responses were seen as early as 1 week post-dose; and

• o Complete responses were observed as early as week 2 post-dose.

• o UAS7 reductions of as much as 29 points were noted 4 weeks post-dose (120mg Q12W); and

Text added vs the prior filing · source: 10-Q · 2026-05-14

• We, from time to time, may be party to litigation arising in the ordinary course of business. On September 19, 2025, a shareholder class action complaint captioned Grant v. Jasper Therapeutics, Inc., et al. (Case No. 25-cv-08010) was filed in the United States District Court for the Northern Distric…

• In addition, on November 5, 2025, a shareholder derivative complaint captioned Bardauskas v. Martell, et al. (Case No. 25-cv-09561) was filed in the United States District Court for the Northern District of California, and on December 22, 2025, another shareholder derivative complaint was filed in t…

• We believe that we are not currently a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Text removed vs the prior filing · source: 10-Q · 2025-11-10

• We, from time to time, may be party to litigation arising in the ordinary course of business. On September 19, 2025, a shareholder class action complaint was filed in the United States District Court for the Northern District of California captioned Grant v. Jasper Therapeutics, Inc., et al. (Case N…

• We believe that we are not currently a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations or cash flows.

Text added vs the prior filing · source: 10-Q · 2026-05-14

• ● elect to continue development of briquilimab in allergic asthma;

• As of March 31, 2026, $93.5 million remains allocated and available under the ATM Prospectus and approximately $170.0 million remains available and unallocated under the Shelf Registration Statement. However, as of March 31, 2026, the aggregate market value of our common stock held by non-affiliates…

Text removed vs the prior filing · source: 10-Q · 2025-11-10

• ● incur costs associated with our investigation into a drug product lot used in our Phase 1b/2a BEACON study in Chronic Spontaneous Urticaria (“CSU”) and Phase 1b/2a ETESIAN study in asthma, and the results of such investigation;

• ● continue the Phase 1b/2a clinical trial of subcutaneous briquilimab for the treatment of CIndU;

• ● may elect to continue development of briquilimab in allergic asthma;

• As of November 6, 2025, $93.5 million remains allocated and available under the ATM Prospectus and approximately $170.0 million remains available and unallocated under the Shelf Registration Statement.

• We may not realize the expected benefits from our corporate reorganization and workforce reduction and we may incur additional costs implementing it or other difficulties or unexpected consequences.